Portfolio Committee Decision â€“ Spironolactone (Adult Female Acne)

Despite strong off-label adoption and dermatologist familiarity,
spironolactone was not prioritized for formal label expansion.

Key limiting factors included generic positioning, monitoring burden,
and limited pricing power relative to branded dermatology assets.
